Lumos Pharma, Inc. (LUMO) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Austin, TX, United States. El CEO actual es Richard J. Hawkins.
LUMO tiene fecha de IPO 2011-11-11, 30 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $37.54M.
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
